Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial

https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(23)00216-1/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=271757280&_hsenc=p2ANqtz-9KRGiw0ihd1W9tcLKQ1Is4Ou-6LOFH22PZuD9guoSkmoFMwpmCw5itmcqZBvU6u-UGVd0cmgCBr23pQLcN12fUj0NRwA&utm_content=271743104&utm_source=hs_email